Research & development costs account for Axis-Shield first-half profits surprise
This article was originally published in Clinica
Executive Summary
Axis-Shield, the Anglo-Norwegian in vitro diagnostics group, surprised analysts when it reported a first-half pre-tax net profit of just £1.2m ($2.3m), against expectations of £1.6-1.8m.